Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Trifecta-Heart cfDNA-MMDx Study

NCT04707872 · View on ClinicalTrials.gov ↗

Study Summary

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST MMDx diagnostic test
  • DIAGNOSTIC_TEST Prospera
  • DIAGNOSTIC_TEST HLA antibody

Study Locations (12)

Other

  • Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute — Darlinghurst
  • Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9 — Prague
  • Heart Failure and Heart Transplant Unit, University of Bologna — Bologna
  • Silesian Center for Heart Diseases (Ś!ąskie Centrum Chorób Serca w Zabrzu — Zabrze
  • Advanced Heart Failure Transplant Unit — A Coruña

Arkansas

  • Baptist Health Institute for Research and Innovation — Little Rock

Florida

  • Tampa General Hospital, 409 Bayshore Blvd. — Tampa

New Jersey

  • Columbia University Medical Center, Columbia Interventional Cardiovascular Care — West New York

New York

  • Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL — The Bronx

Texas

  • Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute — Dallas

Utah

  • Cardiovascular Medicine, University of Utah Health — Salt Lake City

Alberta

  • Division of Cardiology, University of Alberta — Edmonton

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-06-01
Est. Completion 2027-07

Sponsor

University of Alberta

135 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04707872

The ClinicalTrials.gov registry entry for NCT04707872 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 135 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Transplant Rejection appearing as the primary indexed condition, and to 3 interventions — of which MMDx diagnostic test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04707872 reports 12 study locations spanning 8 distinct geographic areas — top geographies include Other, Arkansas, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04707872 about?

NCT04707872 is a clinical study titled "Trifecta-Heart cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

What is the current status of trial NCT04707872?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-01. Estimated completion is 2027-07.

What conditions does trial NCT04707872 study?

This clinical trial studies the following conditions: Heart Transplant Rejection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04707872?

The interventions under investigation include: MMDx diagnostic test (DIAGNOSTIC_TEST), Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04707872?

This trial is sponsored by University of Alberta, which has 135 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04707872 being conducted?

This trial has 12 study locations across Arkansas, Florida, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial